Gilead 1Q Revenues: $7.8 billion (+3%) 1Q Earnings: $3.6 billion (-16%) Comments: Antiviral product sales, which include HIV and liver disease areas, were $7.2 billion, up 3%. In the U.S., antiviral product sales were down 18% in the quarter to $4.0 billion, primarily due to a decline in sales of Harvoni, partially offset by increases in Sovaldi sales, Truvadaand Genvoya, which was launched in the U.S. in November 2015. In Europe, antiviral product sales were down 6% to $1.6 billion, pr...